
Panelists discuss how increasing patient comfort with technology and advances in artificial intelligence (AI) and virtual reality (VR) create opportunities for integrating prescription digital therapeutics (PDTs) into schizophrenia care, while emphasizing the need for clinician education and preserving the human connection.